Medtronic, Inc. (MDT) Micra FDA Letter is Unlikely to Derail Long Term Potential but Does Create Near Term Risk - Wells Fargo
Tweet Send to a Friend
Wells Fargo analyst Larry Biegelsen reiterated an Overweight rating and $144.00 price target on Medtronic, Inc. (NYSE: MDT) after conducting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
